BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34354699)

  • 21. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
    Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
    Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
    Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
    Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy.
    Brito Mde F; Ximenes RA; Gallo ME; Bührer-Sékula S
    Rev Soc Bras Med Trop; 2008; 41 Suppl 2():67-72. PubMed ID: 19618079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
    Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
    Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher incidence of viable Mycobacterium leprae within the nerve as compared to skin among multibacillary leprosy patients released from multidrug therapy.
    Shetty VP; Suchitra K; Uplekar MW; Antia NH
    Lepr Rev; 1997 Jun; 68(2):131-8. PubMed ID: 9217352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of constituents of MDT regimen for leprosy with Mycobacterium leprae HSP18: impact on its structure and function.
    Chakraborty A; Ghosh R; Biswas A
    FEBS J; 2022 Feb; 289(3):832-853. PubMed ID: 34555271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
    Pönnighaus JM; Boerrigter G
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
    Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):250-8. PubMed ID: 10575404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in cellular response to mycobacterial antigens and cytokine production patterns in leprosy patients during multiple drug therapy.
    Trao VT; Huong PL; Thuan AT; Anh DD; Trach DD; Rook GA; Wright EP
    Immunology; 1998 Jun; 94(2):197-206. PubMed ID: 9741341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
    Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
    Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
    Kaur I; Dogra S; Kumar B; Radotra BD
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India.
    Lavania M; Jadhav RS; Chaitanya VS; Turankar R; Selvasekhar A; Das L; Darlong F; Hambroom UK; Kumar S; Sengupta U
    Lepr Rev; 2014 Sep; 85(3):177-85. PubMed ID: 25509718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is drug-resistant Mycobacterium leprae a real cause for concern?: First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment.
    Guerrero MI; Colorado CL; Torres JF; León CI
    Biomedica; 2014 Apr; 34 Suppl 1():137-47. PubMed ID: 24968045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment.
    Eichelmann K; González González SE; Salas-Alanis JC; Ocampo-Candiani J
    Actas Dermosifiliogr; 2013 Sep; 104(7):554-63. PubMed ID: 23870850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
    Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
    Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z; Zhang R; Zhou D; Chen J
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term evaluation of immune status in leprosy patients undergoing multiple drug therapy.
    Vu TT; Hoang TL; Nguyen DQ; Ho ML; Nguyen DH; Le TH; Dang DT; Nguyen QA; Le TP; Tran HK
    Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):365-73. PubMed ID: 7963908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycobacterium leprae DNA content, cellular and cytokine patterns in skin lesions of leprosy patients undergoing multidrug therapy (MDT).
    Flad HD; Richter E; Schlüter C; Duchrow M; Arnoldi J; Hahn M; Graf von Ballestrem W; Alvarenga AE; Gerdes J
    Immunobiology; 1994 Oct; 191(4-5):388-94. PubMed ID: 7713552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy.
    Bach MA; Wallach D; Flageul B; Hoffenbach A; Cottenot F
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):256-67. PubMed ID: 3522769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
    Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
    Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.